Mirum Pharmaceuticals, Inc.

For the period ended Jun 30, 2026. Filed Aug 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 5, 2026

MIRM$94.42+1.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(In thousands, except share and per share data)

	Three Months Ended June 30,		Six Months Ended June 30,
	2026	2025	2026	2025
Revenue:
Product sales, net	$176,243	$127,785	$336,125	$239,370
Operating expenses:
Cost of sales	30,348	23,421	59,153	46,439
Research and development	90,528	46,067	188,438	87,111
Acquired in-process research and development	16,435	—	742,737	5,000
Selling, general and administrative	81,469	63,286	177,799	120,992
Total operating expenses	218,780	132,774	1,168,127	259,542
Loss from operations	(42,537)	(4,989)	(832,002)	(20,172)
Other income (expense):
Interest income	3,851	3,033	7,252	6,056
Interest expense	(2,618)	(3,589)	(6,234)	(7,185)
Other (expense) income, net	(24,234)	86	(24,234)	2,194
Net loss before provision for income taxes	(65,538)	(5,459)	(855,218)	(19,107)
Provision for income taxes	1,689	402	2,164	1,431
Net loss	$(67,227)	$(5,861)	$(857,382)	$(20,538)
Net loss per share, basic and diluted	$(1.06)	$(0.12)	$(14.03)	$(0.42)
Weighted-average shares of common stock used to compute net loss per share, basic and diluted	63,374,183	49,726,823	61,125,097	49,310,255

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.